Archive | Drug Injury Lawyer RSS feed for this section

Kidney Failure Treatment: Dialysis

Healthy kidneys clean the blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your body healthy.  When a person’s kidneys fail, harmful wastes build up in the body, blood pressure may rise, and the body may retain excess fluid and not make enough red blood cells.  Treatment for kidney failure [...]

Comments { 0 }

FDA sends Zicam warning letter

June 16, 2009 Dear Mr. Hemelt: This letter concerns your firm’s marketing of the products Zicam Cold Remedy Nasal Gel, Zicam Cold Remedy Gel Swabs, and Zicam Cold Remedy Swabs, Kids Size. FDA has concluded that these products may pose a serious risk to consumers who use them. Specifically, FDA has received more than 130 [...]

Comments { 0 }

FDA warns about Zicam Injury

On June 16, 2009, the Food and Drug Administration (FDA) warned consumers to stop using and discard three zinc-containing Zicam intranasal products due to Zicam related injuries. The products may cause a loss of sense of smell. Intranasal products are administered through the nose. What products are affected by this warning? FDA’s action affects Zicam’s [...]

Comments { 0 }

FDA scientists blast Agency as corrupt

This is a letter to President Obama from FDA Scientists within the Agency. Dear Mr. President: The purpose of this letter is to draw your attention to the frustration and outrage that FDA physicians and scientists, public advocacy groups, the press, and the American people, have repeatedly expressed over the misdeeds of FDA officials. Recent [...]

Comments { 0 }

Acute phosphate nephropathy linked to laxatives

[Posted 05/05/2006] FDA notified healthcare professionals and consumers of reports of acute phosphate nephropathy, a type of acute renal failure, that is a rare, but serious adverse event associated with the use of oral sodium phosphates (OSP) for bowel cleansing. Documented cases of acute phosphate nephropathy include 21 patients who used an OSP solution (such [...]

Comments { 0 }